Recent studies have found that patients with Sjögren disease, particularly those with mucosa-associated lymphoid tissue (MALT) lymphoma, may benefit from a more aggressive treatment approach. The studies confirmed that rheumatoid factor (RF) is a key predictor of Sjögren disease–related MALT lymphoma and that systemic treatment strategies can reduce disease activity and the risk of lymphoma relapse. These findings suggest that a combination of chemotherapy and anti-CD20 therapy with rituximab as a first-line treatment may be more effective in managing the disease. Further research is needed to explore biomarkers for lymphoma development and optimal treatment strategies for Sjögren disease–related lymphoma.
Source link
New Insights into Management of Sjögren-Related Lymphoma
